The following submission rules were established by the APSA Committee on the Annual Meeting: Submit up to two proposals. Additional proposals from the same author or organizer will not be accepted. It is possible for others to submit individuals to additional roles outside their two proposals,...
For more information about the meeting, visit the APSA 2024 Annual Meeting page. Try Stata for free by requesting a short-term evaluation license. To be notified of future software releases, free webinars, classroom and web-based training courses, and more, sign up for email alerts. Stata...
Join us for the 120th American Political Science Association (APSA) Annual Meeting & Exhibition, September 5-8, 2024, held in Philadelphia, Pennsylvania! The 2024 conference theme is “Democracy: Retrenchment, Renovation, & Reimagination.” The APSA Annual Meeting features a variety of sessions,...
UpFrontPSMA研究是首项证实177Lu-PSMA-617在mHSPC患者中具有临床获益的随机II期临床试验13,其主要终点是第48周时前列腺特异性抗原(PSA)不可检测率(≤0.2ng/ml)。结果显示,相较于单独接受多西他赛治疗组,177Lu-PSMA-617序贯多西他赛治疗...
SASE 2022 34th Annual Meeting 商务 2023 APSA Annual Meeting 商务 2024 APSA Annual Meeting 商务 APSA 2022 Meeting 商务 GSA Conference 2024 商务 ISAnet Events 效率 Regional Studies Association 效率 LERA Mobile 商务 Association for Jewish Studies ...
PSA50反应率和ORR结果也提示¹⁷⁷Lu-PSMA-617组(PSA50反应率:57.6% vs 20.4%;ORR:50.7% vs 14.9%)效果更佳,其中¹⁷⁷Lu-PSMA-617组的完全缓解率(CR)更是高达21.1%,对照组仅为2.7%。 PSMAfore的事后分析显示,¹⁷⁷Lu-PSMA-617组和更换ARPI组既往接受阿比特龙或恩扎卢胺治疗的比例相当,...
徐萍博士是罗德岛大学政治学系教授及研究生项目主任,美国政治学协会(American Political Science Association, APSA)公共政策部主席。她的研究兴趣包括福利政策、移民政策、政治经济学、公共舆论、政治传播等领域。她的成果发表在American Journ...
海创药业(688302.SH)自主研发的口服PROTAC药物HP518的临床研究数据将于2024年5月31日至6月4日在美国芝加哥市举行的2024年度美国临床肿瘤学会年会(2024 ASCO Annual Meeting)上发布。 HP518临床研究数据 本研究为HP518在mCRPC患者中的首次人体、非随机、开放性、多中心I期剂量递增研究,旨在评价其安全性、耐受性、药...
Baseline characteristics were similar (F + vs F-) with median (IQR) age 63 (59–66) vs 64 (58–68) years, PSA 5.3 (4.5–7.2) vs 5.4 (4.3–7.0) ng/mL, and 38/53 (72%) vs 28/42 (67%) had PI-RADS 2 on mpMRI. Technical parameters were similar between groups, with ...
即Gleason评分小于6且涉及不到三分之一的核心，并且任何一个核心的PSA水平低于10。